These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 24377511)
1. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Bian J; Li B; Kou XJ; Liu TZ; Ming L Asian Pac J Cancer Prev; 2013; 14(11):6241-3. PubMed ID: 24377511 [TBL] [Abstract][Full Text] [Related]
2. Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer. Chen C; Chen Q; Zhao Q; Liu M; Guo J Ann Clin Lab Sci; 2017 May; 47(3):260-263. PubMed ID: 28667025 [TBL] [Abstract][Full Text] [Related]
3. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1. Yang J; Tang A; Ma J; Sun X; Ming L Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773 [TBL] [Abstract][Full Text] [Related]
4. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis. Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638 [TBL] [Abstract][Full Text] [Related]
5. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Donach M; Yu Y; Artioli G; Banna G; Feng W; Bast RC; Zhang Z; Nicoletto MO Tumour Biol; 2010 Jun; 31(3):209-15. PubMed ID: 20393825 [TBL] [Abstract][Full Text] [Related]
6. Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Nishida Y; Kohno K; Kawamata T; Morimitsu K; Kuwano M; Miyakawa I Gynecol Oncol; 1995 Mar; 56(3):357-61. PubMed ID: 7705668 [TBL] [Abstract][Full Text] [Related]
7. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592 [TBL] [Abstract][Full Text] [Related]
8. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma]. Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162 [TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854 [TBL] [Abstract][Full Text] [Related]
10. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054 [TBL] [Abstract][Full Text] [Related]
11. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer. Xi QP; Pu DH; Lu WN Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263 [TBL] [Abstract][Full Text] [Related]
12. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays. Yedema C; Massuger L; Hilgers J; Servaas J; Poels L; Thomas C; Kenemans P Int J Cancer Suppl; 1988; 3():61-7. PubMed ID: 3209301 [TBL] [Abstract][Full Text] [Related]
13. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer]. Kobayashi H; Sumimoto K; Terao T; Kawashima Y Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1501-6. PubMed ID: 2573640 [TBL] [Abstract][Full Text] [Related]
14. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer. Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284 [TBL] [Abstract][Full Text] [Related]
15. CA125 and HE4: Measurement Tools for Ovarian Cancer. Zhao T; Hu W Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Emoto S; Ishigami H; Yamashita H; Yamaguchi H; Kaisaki S; Kitayama J Gastric Cancer; 2012 Apr; 15(2):154-61. PubMed ID: 21892754 [TBL] [Abstract][Full Text] [Related]
17. Increase of serum tumor marker concentrations by interferon-alpha. Gebauer G; Jaeger W; Thiel G; Lang N Eur J Gynaecol Oncol; 1998; 19(4):363-7. PubMed ID: 9744727 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of carbohydrate antigen 72-4 combined with carbohydrate antigen 15.3 in ovarian cancer, cervical cancer and endometrial cancer. Li M; Men X; Zhang X J BUON; 2020; 25(4):1918-1927. PubMed ID: 33099933 [TBL] [Abstract][Full Text] [Related]
19. Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature. Sagi-Dain L; Lavie O; Auslander R; Sagi S Am J Clin Oncol; 2018 Sep; 41(9):838-844. PubMed ID: 28338481 [TBL] [Abstract][Full Text] [Related]
20. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer. Fayed ST; Ahmad SM; Kassim SK; Khalifa A Dis Markers; 1998 Nov; 14(3):155-60. PubMed ID: 10427474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]